AtaiBeckley (ATAI) has seen its stock soar 213% year-to-date, outperforming the S&P 500 Index. The company focuses on psychedelic-based mental health therapies and has recently achieved significant milestones, including a Breakthrough Therapy designation for its nasal spray to treat depression. The merger between atai Life Sciences and Beckley Psytech further solidified their position in mental health treatments. With a strong pipeline of high-risk, high-reward projects and a disciplined financial strategy, ATAI is considered a long-term bet for investors. Analysts rate the stock a “Strong Buy” with a potential upside of 190% based on current levels.

Read more at Barchart: The 1 Riskiest Investment That Paid Off in 2025